title: [Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma].
abstract: Objective:To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (ARL) .Methods:The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability.Results:The mean age of patients with ARL was 43 (11-67) years. Male versus female was approximately 4∶1. The median CD4(+) T cell count was (146±20) /ml. The Ann Arbor clinical classification showed that 52.8% of the cases were of stage Ⅲ and Ⅳ. Approximately 54.7% of the patients had elevated serum lactate dehydrogenase (LDH) . According to international prognosis index score, 64.2% of the patients were in high risk group. Diffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype. Among 53 cases, 33 cases (62.3%) received combination of anti-HIV therapy and anti-NHL (CHOP) chemotherapy regimen, 8 cases (15.1%) only received anti-HIV therapy, and 12 cases (22.6%) asked for alleviative treatment. Median survival time was (6.0±1.3) months for ARL cases versus (48.0±10.0) months for controls (P<0.05) . After eliminating cases who did not receive anti-lymphoma treatment, ARL cases showed a lower 1-year OS rates than control group (60.6% versus 83.0%) , but no difference about 2-, 3- and 5-year OS rates (53.5% versus 60.5%, 48.1% versus 45.9%, and 39.1% versus 27.5%, respectively) .Conclusions:ARL is more common in young adults; one-year mortality rate is high. Anti-HIV therapy combined with anti-NHL therapy could significantly improve the prognosis of ARL patients. CHOP regimen may be more suitable for ARL patients.
authors.forename: K Y
authors.initials: KY
authors.lastname: Sun
authors.forename: X E
authors.initials: XE
authors.lastname: Gui
authors.forename: D
authors.initials: D
authors.lastname: Deng
authors.forename: Y
authors.initials: Y
authors.lastname: Xiong
authors.forename: L P
authors.initials: LP
authors.lastname: Deng
authors.forename: S C
authors.initials: SC
authors.lastname: Gao
authors.affiliation: Department of Infectious Disease, Zhongnan Hospital of Wuhan University. Wuhan 430071, China.
authors.forename: Y X
authors.initials: YX
authors.lastname: Zhang
mesh_terms: D000163:Acquired Immunodeficiency Syndrome; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D006801:Humans; D016483:Lymphoma, AIDS-Related; D008228:Lymphoma, Non-Hodgkin; D008297:Male; D008875:Middle Aged; D011239:Prednisolone; D011379:Prognosis; D012189:Retrospective Studies; D014750:Vincristine; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
keywords: Acquired immunodeficiency syndrome; Lymphoma, non-Hodgkin; Retrospective studies; Survival analysis